Clinical Trial: The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies

U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07023861) titled 'The Exploration of Novel Radionuclide-labeled HER2-targeting Antibodies in the Diagnosis of HER2-positive Malignancies' on May 12.

Brief Summary: The purpose of this study is to develop and clinically evaluate 89Zr-labeled HER2-targeted antibodies in diagnosis and screening of HER2-positive cancer patients.

Study Start Date: July 01

Study Type: INTERVENTIONAL

Condition: Breast Cancer Gastric Cancer (GC) Urothelial Carcinoma (UC)

Intervention: DRUG: 18F-FDG

18F-FDG is administered through a superficial dorsal vein, and the patient is given a dose of about 0.1-0.15 mCi/kg.

DRUG: 89Zr-LNCab190

89Zr-LNCab190 is administered thr...